Aptevo Therapeutics Stock Price, News & Analysis (NASDAQ:APVO)

Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."

Aptevo Therapeutics Inc (NASDAQ:APVO) posted its quarterly earnings data on Friday, August, 9th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.33) by $0.03. The biotechnology company earned $7.36 million during the quarter, compared to analysts' expectations of $6.95 million. Aptevo Therapeutics had a negative return on equity of 148.97% and a negative net margin of 195.98%. View Aptevo Therapeutics' Earnings History.

Aptevo Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for Aptevo Therapeutics.

3 brokerages have issued 12-month price targets for Aptevo Therapeutics' shares. Their predictions range from $4.50 to $14.00. On average, they anticipate Aptevo Therapeutics' share price to reach $10.1667 in the next twelve months. This suggests a possible upside of 1,373.4% from the stock's current price. View Analyst Price Targets for Aptevo Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aptevo Therapeutics.

Press coverage about APVO stock has been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aptevo Therapeutics earned a news impact score of -1.3 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Aptevo Therapeutics.

Aptevo Therapeutics saw a decline in short interest during the month of August. As of August 15th, there was short interest totalling 233,400 shares, a decline of 5.5% from the July 15th total of 246,900 shares. Based on an average trading volume of 585,200 shares, the short-interest ratio is presently 0.4 days. Currently, 1.3% of the shares of the company are short sold. View Aptevo Therapeutics' Current Options Chain.

Some companies that are related to Aptevo Therapeutics include Chembio Diagnostics (CEMI), OASMIA PHARMACE/ADR (OASM), Galmed Pharmaceuticals (GLMD), Relmada Therapeutics (RLMD), Sesen Bio (SESN), Corvus Pharmaceuticals (CRVS), Savara (SVRA), Processa Pharmaceuticals (PCSA), Avenue Therapeutics (ATXI), Aduro BioTech (ADRO), Elite Pharmaceuticals (ELTP), CELYAD SA/ADR (CYAD), Verastem (VSTM), Humanigen (HGEN) and Aquinox Pharmaceuticals (AQXP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Synergy Pharmaceuticals (SGYP), Zynerba Pharmaceuticals (ZYNE), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), Alibaba Group (BABA), Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), BIOLINERX LTD/S (BLRX) and Cara Therapeutics (CARA).

Aptevo Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (8.70%), Point72 Asset Management L.P. (5.21%), Renaissance Technologies LLC (3.65%), Vanguard Group Inc. (2.49%), Acadian Asset Management LLC (1.40%) and Worth Venture Partners LLC (0.99%). Company insiders that own Aptevo Therapeutics stock include Barbara Lopez Kunz, Daniel Abdun-Nabi, Fuad El-Hibri, Grady Grant III, Marvin L White, Randy Joe Maddux and Zsolt Harsanyi. View Institutional Ownership Trends for Aptevo Therapeutics.

APVO stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and BlackRock Inc.. View Insider Buying and Selling for Aptevo Therapeutics.

APVO stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Renaissance Technologies LLC, Point72 Asset Management L.P., A.R.T. Advisors LLC, Algert Global LLC, Bank of New York Mellon Corp, Stonepine Capital Management LLC and Worth Venture Partners LLC. Company insiders that have bought Aptevo Therapeutics stock in the last two years include Barbara Lopez Kunz, Daniel Abdun-Nabi, Fuad El-Hibri, Grady Grant III, Marvin L White, Randy Joe Maddux and Zsolt Harsanyi. View Insider Buying and Selling for Aptevo Therapeutics.

Shares of APVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of APVO stock can currently be purchased for approximately $0.69.

Aptevo Therapeutics has a market capitalization of $31.12 million and generates $23.07 million in revenue each year. The biotechnology company earns $-53,690,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis. Aptevo Therapeutics employs 118 workers across the globe.View Additional Information About Aptevo Therapeutics.

The official website for Aptevo Therapeutics is http://www.aptevotherapeutics.com/.

Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company can be reached via phone at 206-838-0500 or via email at [email protected]